Protox's data shows PRX302 may have potential for prostate cancer

By Lisa Kerner

Erie, Pa., April 3 - Protox Therapeutics Inc. said preclinical data demonstrates PRX302's validity as a treatment for prostate cancer and benign prostatic hyperplasia.

The data will be presented in a poster session at the 97th Meeting of the American Association of Cancer Research in Washington, D.C., according to a news release.

The poster, entitled "PSA-Activated Proaerolysin as a Prostate Specific Cancer Therapy," summarizes data generated from studies conducted at the Cancer Research Institute at Scott & White Hospital in Temple, Texas.

Protox said the results confirm that PRX302, its lead drug, is preferentially activated by PSA (prostate specific antigen) and selectively kills PSA producing cells. This selectivity could lead to an effective treatment with less toxicity than current treatments for both prostate cancer and benign prostatic hyperplasia.

Protox has received Food and Drug Administration clearance to begin a phase 1 clinical trial with PRX302 for the treatment of localized prostate cancer. The trial is expected to begin in the second quarter of 2006, the release stated.

Vancouver, B.C.-based Protox is a development-stage company focused on advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.